An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.
Inclusion Criteria:
Exclusion Criteria:
Encinitas, California 92008, United States
Jacksonville, Florida 32256, United States
Annapolis, Maryland 21401, United States
Madison, Wisconsin 53792, United States
Innsbruck, 6020, Austria
Vienna, 1090, Austria
Vienna, 1140, Austria
Salvador, Bahia, Estado de Bahia 40170-380, Brazil
Brasília, Federal District 70200-730, Brazil
Marseille, 13915, France
Esslingen am Neckar, 73730, Germany
Homburg/Saar, 66421, Germany
Rome, Lazio 00152, Italy
Genoa, Liguria 16132, Italy
Pisa, Tuscany 56124, Italy
Ehime, 791-0280, Japan
Mexico City, Mexico